Qube Research & Technologies (QRT)’s Ocular Therapeutix OCUL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-531,816	Closed	-$4.5M	–	3892
2026 Q1	$4.5M	Sell	531,816 -237,958	-31%	-$2.27M	0.01%	1718
2025 Q4	$9.35M	Buy	769,774 +738,922	+2,395%	+$8.98M	0.01%	1385
2025 Q3	$361K	Buy	+30,852	New	+$369K	﹤0.01%	2801
2022 Q1	–	Sell	-78,242	Closed	-$545K	–	2836
2021 Q4	$545K	Buy	78,242 +46,617	+147%	+$362K	﹤0.01%	1523
2021 Q3	$316K	Sell	31,625 -65,346	-67%	-$734K	﹤0.01%	1466
2021 Q2	$1.38M	Buy	96,971 +76,202	+367%	+$1.16M	0.02%	823
2021 Q1	$341K	Buy	+20,769	New	+$400K	0.01%	1392
2020 Q3	–	Sell	-44,349	Closed	-$369K	–	1986
2020 Q2	$369K	Buy	+44,349	New	+$294K	0.01%	1227

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Qube Research & Technologies (QRT)'s OCUL Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 531,816 shares — an estimated $4.5M sold.

Qube Research & Technologies (QRT) first reported a position in OCUL in Q2 2020 and held it in 8 quarters. The position peaked at $9.35M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Qube Research & Technologies (QRT) reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 531,816 Ocular Therapeutix shares in Q2 2026, an estimated $4.5M.
Qube Research & Technologies (QRT) first reported a position in Ocular Therapeutix in Q2 2020 and held it in 8 quarters.
Qube Research & Technologies (QRT)'s Ocular Therapeutix position peaked at $9.35M in Q4 2025.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.